COVAXX & United Neuroscience merge to form Vaxxinity: advancing vaccine technology for chronic and infectious diseases
In April 2021, COVAXX and United Neuroscience, subsidiaries of United Biomedical, merged to form Vaxxinity, Inc., based in Dallas, Texas. The company is focused on developing synthetic peptide vaccines for chronic and infectious diseases, including Alzheimer’s, Parkinson’s, COVID-19, migraines, and hypercholesterolemia.
Vaxxinity’s innovative approach aims to tackle conditions previously considered too complex for vaccines. By leveraging synthetic peptides, Vaxxinity is at the forefront of vaccine technology, with the potential to transform the biotechnology landscape and improve millions of lives.
Sources:
